Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Alisporivir

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Alisporivir: Sponsors, patents, clinical trial progress

Alisporivir is an investigational drug.

There have been 14 clinical trials for Alisporivir. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis A. The leading clinical trial sponsors are Debiopharm International SA, Novartis Pharmaceuticals, and Enanta Pharmaceuticals.

There are three US patents protecting this investigational drug and eighty international patents.

Recent Clinical Trials for Alisporivir
Two-way Interaction Between Alisporivir and EDP239Enanta PharmaceuticalsPhase 1
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an OptionDebiopharm International SAPhase 2
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve PatientsDebiopharm International SAN/A

See all Alisporivir clinical trials

Clinical Trial Summary for Alisporivir

Top disease conditions for Alisporivir
Top clinical trial sponsors for Alisporivir

See all Alisporivir clinical trials

US Patents for Alisporivir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Alisporivir   Start Trial Methods for treating HCV AbbVie Inc. (North Chicago, IL)   Start Trial
Alisporivir   Start Trial Methods for treating HCV AbbVie Inc. (North Chicago, IL)   Start Trial
Alisporivir   Start Trial Process for the manufacture of cyclic undecapeptides Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Alisporivir

Drugname Country Document Number Estimated Expiration Related US Patent
Alisporivir Argentina 088463 2031-10-21   Start Trial
Alisporivir Austria 514003 2031-10-21   Start Trial
Alisporivir Australia 2013201406 2031-10-21   Start Trial
Alisporivir Brazil 112014006314 2031-10-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.